• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Free Sialic Acid Storage Disorders

, MD, PhD and , MD, PhD.

Author Information
, MD, PhD
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland
, MD, PhD
Clinical Director, National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

Initial Posting: ; Last Update: June 6, 2013.

Summary

Disease characteristics. The allelic disorders of free sialic acid metabolism — Salla disease, intermediate severe Salla disease, and infantile free sialic acid storage disease (ISSD) — are neurodegenerative disorders resulting from increased lysosomal storage of free sialic acid. The mildest phenotype is Salla disease, which is characterized by normal appearance and neurologic findings at birth followed by slowly progressive neurologic deterioration resulting in mild to moderate psychomotor retardation, spasticity, athetosis, and epileptic seizures. The most severe phenotype is ISSD, characterized by severe developmental delay, coarse facial features, hepatosplenomegaly, and cardiomegaly; death usually occurs in early childhood.

Diagnosis/testing. Free sialic acid storage disorders result from defective free sialic acid transport out of lysosomes as a consequence of mutations in SLC17A5, encoding the lysosomal transport protein sialin. The diagnosis of a free sialic acid storage disorder is suggested by significantly elevated free (i.e., unconjugated) sialic acid (referred to as N-acetylneuraminic acid, a negatively charged sugar) in urine and/or cerebrospinal fluid using the fluorimetric thiobarbituric acid assay, thin-layer chromatography, or mass spectrometry. The diagnosis is established either by demonstrating lysosomal (rather than cytoplasmic) localization of elevated free sialic acid or by identifying disease-causing mutations in SLC17A5.

Management. Treatment of manifestations: Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures.

Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.

Genetic counseling. The free sialic acid storage disorders are inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Prenatal testing for pregnancies at increased risk is possible by measuring free sialic acid either in chorionic villus biopsy specimens (obtained by chorionic villus sampling at ~10-12 weeks' gestation) or in amniocytes (obtained by amniocentesis usually performed at ~15-18 weeks' gestation). Carrier testing for relatives at increased risk and prenatal testing for pregnancies at increased risk is an option if both disease-causing mutations have been identified in a family.

GeneReview Scope

Free Sialic Acid Storage Disorders: Included Disorders
  • Salla disease
  • Infantile free sialic acid storage disease

For synonyms and outdated names see Nomenclature.

Diagnosis

Clinical Diagnosis

There are no consensus clinical diagnostic criteria for Salla disease. The diagnosis of Salla disease is suspected in individuals who manifest truncal ataxia and hypotonia at age approximately one year, developmental delays and growth retardation in early childhood, and severe cognitive and motor impairment or intellectual disability in adulthood. The association of intellectual disability, spasticity, ataxia, myelination defects, and facial coarsening in adulthood is suggestive of Salla disease.

The diagnosis of infantile free sialic acid storage disease (ISSD) is suspected in individuals with early multisystemic involvement including: hydrops fetalis, hepatosplenomegaly, failure to thrive, increasingly coarse facial features, neurologic deterioration typical of a lysosomal storage disease, dysostosis, and early death [Helip-Wooley et al 2007].

Testing

Affected individuals

  • Free sialic acid. Sialic acids are a family of negatively charged sugars, one of which, N-acetylneuraminic acid, is elevated in lysosomes in free sialic acid storage disorders:
    • Urinary excretion of free sialic acid, measured by the fluorimetric thiobarbituric acid assay, thin-layer chromatography or mass spectrometry, is elevated about tenfold in individuals with Salla disease and about 100-fold in individuals with ISSD. HPLC/tandem mass spectrometry is also able to detect free sialic acid in urine [Valianpour et al 2004].

      Note: (1) In the thiobarbituric acid assay, interfering substances may lower the measurement and chromophores may contribute to absorbance, creating a false measurement. (2) In thin-layer chromatography, an elevation of free sialic acid may be overlooked.
  • Cultured fibroblasts from individuals with Salla disease and individuals with ISSD show increased concentration of free sialic acid [Renlund et al 1986].
  • Lysosomal localization of free sialic acid, suspected by electron microscopy of biopsy material (e.g., skin or liver), confirms the diagnosis of a free sialic acid storage disorder. Subcellular fractionation studies can demonstrate the lysosomal localization of the elevated free sialic acid.

Carriers. Biochemically based carrier testing is not feasible.

Molecular Genetic Testing

Gene. SLC17A5 is the only gene in which mutations are known to cause Salla disease and ISSD.

Clinical testing

Table 1. Summary of Molecular Genetic Testing Used in Free Sialic Acid Storage Disorders

Gene 1Test MethodMutations Detected 2Mutation Detection Frequency by Test Method 3
SLC17A5Sequence analysisSequence variants 4Unknown
Targeted mutation analysis / mutation scanning of select exons 5p.Arg39Cys 6Homozygous p.Arg39Cys in individuals of Finnish origin (91%) 7
Deletion/duplication analysis 8Exonic or whole gene deletions 8Unknown

1. See Table A. Genes and Databases for chromosome locus and protein name.

2. See Molecular Genetics for information on allelic variants.

3. The ability of the test method used to detect a mutation that is present in the indicated gene

4. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

5. Mutation scanning of exon 2 may be used to detect the p.Arg39Cys mutation.

6. The prevalence of p.Arg39Cys is high in the founder region of northeastern Finland (see Prevalence).

7. Finnish individuals with Salla disease [Aula et al 2000]

8. Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.

Testing Strategy

To confirm/establish the diagnosis in a proband. Strong evidence for a sialic acid storage disorder (in order of the frequency of use in a clinical setting):

1.

Urinary excretion of sialic acid on the order of 100-fold normal

2.

Sequence analysis of SLC17A5 that reveals biallelic, well-described pathogenic mutations

3.

Elevated fibroblast concentration of free sialic acid

4.

Cell biologic studies showing localization of sialic acid to lysosomes

Supportive evidence for a sialic acid storage disorder:

1.

Characteristic physical findings

2.

Hypomelination evident on brain MRI

3.

Urinary excretion of sialic acid on the order of tenfold normal

4.

Elevated CSF sialic acid with or without elevated urinary excretion of sialic acid

5.

Pathogenic-appearing but novel biallelic SLC17A5 mutations detected by sequence analysis

Carrier testing of at-risk relatives requires prior identification of the disease-causing mutations in the family.

Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.

Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies may be performed using molecular or biochemical studies:

  • Testing of at-risk pregnancies using SLC17A5 sequence analysis requires prior identification of the disease-causing mutations in the family.
  • For suspected ISSD, cultured amniocytes or tissue obtained by CVS can be used for measurement of tissue free sialic acid levels.
  • For suspected Salla disease, cultured amniocytes may have sialic acid levels that are inadequately elevated to reliably differentiate them from the sialic acid levels seen in normals/carriers. Therefore, uncultured tissue derived from CVS is the preferred specimen for free sialic acid measurement [Salomaki et al 2001, Aula & Aula 2006, Gopaul & Crook 2006].

Clinical Description

Natural History

The phenotypes of the allelic disorders of free sialic acid metabolism — Salla disease, intermediate severe Salla disease, and infantile free sialic acid storage disease (ISSD) — range from mild to severe. All are neurodegenerative disorders resulting from increased lysosomal storage of free sialic acid [Aula & Gahl 2001]. Onset varies from apparently unaffected in the newborn period to severely affected prenatally.

Salla Disease

Salla disease is the mildest phenotype [Varho et al 2002], characterized by a normal appearance and normal neurologic findings at birth followed by slowly progressive neurologic deterioration resulting in mild-to-moderate psychomotor retardation [Renlund et al 1983, Alajoki et al 2004]. Muscular hypotonia is often first recognized at approximately age six months. One third of affected children learn to walk. Speech can be limited to single words but understanding of speech is good. Slow developmental progress often continues until the third decade, after which regression can occur.

Some individuals with Salla disease present later in life with spasticity, athetosis, and epileptic seizures, becoming nonambulatory and nonverbal. Affected individuals are characterized as good-humored and sociable [Varho et al 2002].

Abnormal myelination of the basal ganglia and hypoplasia of the corpus callosum are constant and early findings. MRI reveals these predominant white matter changes [Sonninen et al 1999]. Cerebellar white matter changes are also present and can explain the ataxia [Linnankivi et al 2003, Biancheri et al 2004].

In addition to the central dysmyelination, a peripheral dysmyelination with the clinical picture of a polyneuropathy occurs with variable neurologic presentations [Varho et al 2000, Varho et al 2002].

Affected individuals do not have organomegaly, skeletal dysostosis, or abnormal eye findings. In a single individual, growth hormone and gonadotropin deficiencies were observed [Grosso et al 2001].

Life expectancy appears to be shortened, although affected individuals up to age 72 years have been observed.

Intermediate severe Salla disease. Since the advent of molecular studies, phenotypes with a severity between those of Salla disease and ISSD [Aula & Gahl 2001] have been attributed to compound heterozygosity for the Salla disease common mutation p.Arg39Cys and another SLC17A5 mutation [Kleta et al 2003]. Thus the term "intermediate severe Salla disease" was proposed [Aula et al 2000].

Infantile Free Sialic Acid Storage Disease (ISSD)

ISSD, the most severe phenotype, is characterized by severe developmental delays, coarse facial features, hepatosplenomegaly, and cardiomegaly. ISSD can present prenatally and in the neonatal period with nonimmune hydrops fetalis [Lemyre et al 1999, Stone & Sidransky 1999, Froissart et al 2005]. Some affected infants are born prematurely. Other affected infants appear normal at birth but deteriorate and lose milestones during infancy [Kleta et al 2003, Kleta et al 2004]. Seizures are common.

Some infants with ISSD develop proteinuria and nephrotic syndrome [Lemyre et al 1999, Ishiwari et al 2004].

Skeletal changes may include irregular metaphyses, diffuse hypomineralization, club feet, short femurs, enlarged metaphyses, fractures, hip dysplasia, anterior beaking of the dorsal vertebrae, and hypoplasia of the distal phalanges [Froissart et al 2005].

Death usually occurs in early childhood, typically from respiratory infections.

Genotype-Phenotype Correlations

Correlations between the type of SLC17A5 mutation and the severity of the lysosomal free sialic acid storage disease have been identified [Aula et al 2000, Varho et al 2000, Kleta et al 2003]:

  • Homozygosity for the missense mutation p.Arg39Cys, a single Finnish founder mutation, leads to Salla disease, with its slow clinical course of neurologic deterioration.
  • Compound heterozygosity for the p.Arg39Cys mutation and another SLC17A5 mutation leads to intermediate severe Salla disease, as does homozygosity for the p.Lys136Glu mutation [Biancheri et al 2005].
  • Compound heterozygosity for mutations other than p.Arg39Cys leads to the severe phenotype of ISSD, with early onset and multisystemic involvement.

Variable expression has been observed among affected family members [Landau et al 2004].

Penetrance

Free sialic acid storage disorders seem to be fully penetrant. However, Mochel et al [2009] reported a case of two individuals with homozygous p.Lys136Glu mutations, no detectable urinary sialic acid abnormality, and elevated CSF free sialic acid suggesting that penetrance based on urinary studies alone may be incomplete.

Nomenclature

Free sialic acid storage disorders have been and continue to be labeled with different terms, mainly because of the different names used to denote N-acetylneuraminic acid. Although no consensus exists, the terms Salla disease, intermediate severe Salla disease, and ISSD are the most widely accepted; NANA disease is falling into disuse. Further confusion results from the fact that ISSD and Salla disease are often diagnosed without firm molecular proof, and show variable clinical expression in affected individuals.

Prevalence

Salla disease has been reported in approximately 150 individuals, mainly from Finland and Sweden [Aula et al 2000, Erikson et al 2002]. Individuals with molecularly proven Salla disease have been identified outside of Finland and Sweden [Martin et al 2003]. The prevalence of the SLC17A5 mutation p.Arg39Cys is high in the founder region of northeastern Finland, where the carrier frequency is in the range of 1:100 [Aula et al 2000]. Ninety-five percent of individuals of Finnish heritage with Salla disease have the p.Arg39Cys mutation. The prevalence of other SLC17A5 mutations appears to be independent of the geographic origin or ethnicity of affected individuals; their presence has been documented in more than 30 individuals from several countries throughout the world [Lemyre et al 1999, Aula et al 2000, Kleta et al 2003, Martin et al 2003, Sonderby Christensen et al 2003, Kleta et al 2004].

Differential Diagnosis

Increased Urinary and Cellular Free Sialic Acid

Sialuria. The clinical course of sialuria involves developmental delay and hepatomegaly but does not include severe neurologic involvement or early death [Seppala et al 1999, Enns et al 2001, Leroy et al 2001]. In sialuria, elevation of free sialic acid occurs in the cytoplasm rather than in the lysosome. The only disorders in which significantly elevated urinary and cellular free sialic acid are known to occur are sialuria and the free sialic acid storage disorders (Salla disease and ISSD).

Based on clinical suspicion and the finding of elevated free sialic acid in the urine, one of two steps is taken to distinguish these conditions:

  • The cellular (cytoplasmic versus lysosomal) localization of free sialic acid can be documented; a predominantly lysosomal localization indicates Salla disease or ISSD.

Molecular studies of SLC17A5 (for Salla disease and ISSD) or GNE (for sialuria) can be performed. Of interest, all of the published sialuria-causing mutations in GNE have been localized to a small region of the gene (p.Arg263 – p.Arg266) thought to be important for allosteric feedback regulation [Ferreira et al 1999]. See Sialuria, Molecular Genetics.

Other causes of mild elevation in urinary free sialic acid may exist.

Sialidosis and galactosialidosis. If sialic acid bound to glycoproteins or glycolipids is stored, disorders such as sialidosis caused by sialidase (neuraminidase) deficiency and galactosialidosis caused by combined sialidase and galactosidase deficiency should be considered. These enzyme deficiencies involve lysosomal storage of sialic acid-containing glycoconjugates [Gahl et al 1996]. Both of these disorders have features typical of lysosomal storage diseases but vary widely in their manifestations.

Clinical Findings

Several lysosomal storage disorders display the clinical manifestation of coarse facial features and developmental delays. Other causes of nonimmune hydrops fetalis include: alpha-iduronidase deficiency (MPS1), glycosylceramidase deficiency (Gaucher disease), beta-glucuronidase deficiency, I-cell disease, beta-glucosidase deficiency, acid sphingomyelinase deficiency, acid lipase deficiency, galactosylcerabrosidase deficiency (Krabbe disease), sialidase deficiency, and galactosialidosis.

Note to clinicians: For a patient-specific ‘simultaneous consult’ related to this disorder, go to Image SimulConsult.jpg, an interactive diagnostic decision support software tool that provides differential diagnoses based on patient findings (registration or institutional access required).

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with a free sialic acid storage disorder, the following evaluations are recommended:

  • Neurologic and developmental evaluations to establish a baseline for educational and rehabilitation interventions
  • MRI

    Note: MRI may reveal classic brain findings, but correlations between such findings and disease severity have not been established.
  • Biochemical genetics or neurogenetics consultation

Treatment of Manifestations

The medical and psychosocial management of individuals with free sialic acid storage disorders is symptomatic and supportive.

Management focuses on rehabilitation to optimize mobility and communication.

Programs to foster normal development and assure adequate nutrition should be implemented.

Treatment of seizures follows standard management principles.

Surveillance

Regular evaluation by a rehabilitation specialist may identify potentially helpful interventions.

Evaluation of Relatives at Risk

No routine testing is recommended because adult presentations are unusual and no early interventions are available.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

The free sialic acid storage disorders are inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

  • The parents of an affected child are obligate heterozygotes and thus carry one mutant allele.
  • Heterozygotes (carriers) are asymptomatic.

Sibs of a proband

  • At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
  • Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3.
  • Heterozygotes are asymptomatic.

Offspring of a proband. Because of the severity of the disease, affected individuals are unlikely to reproduce.

Other family members of a proband. Each sib of the proband's parents is at a 50% risk of being a carrier.

Carrier Detection

Carrier testing for at-risk family members is possible if the disease-causing mutations have been identified in the family.

Related Genetic Counseling Issues

Family planning

  • The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing

Biochemical genetic testing. Prenatal testing for pregnancies at increased risk is possible by measuring free sialic acid either in chorionic villus biopsy specimens (obtained by chorionic villus sampling at ~10-12 weeks' gestation) or in amniocytes (obtained by amniocentesis usually performed at ~15-18 weeks' gestation) [Salomaki et al 2001].

Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.

Molecular genetic testing. If the disease-causing mutations have been identified in a family member, prenatal testing for pregnancies at increased risk is possible either through a clinical laboratory or a laboratory offering custom prenatal testing.

Preimplantation genetic diagnosis (PGD) may be an option for some families in which the disease-causing mutations have been identified.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Children Living with Inherited Metabolic Diseases (CLIMB)
    Climb Building
    176 Nantwich Road
    Crewe CW2 6BG
    United Kingdom
    Phone: 0800-652-3181 (toll free); 0845-241-2172
    Fax: 0845-241-2174
    Email: info.svcs@climb.org.uk
  • National Tay-Sachs and Allied Diseases Association, Inc. (NTSAD)
    2001 Beacon Street
    Suite 204
    Boston MA 02135
    Phone: 800-906-8723 (toll-free)
    Fax: 617-277-0134
    Email: info@ntsad.org
  • Myelin Disorders Bioregistry Project
    Email: myelindisorders@cnmc.org

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A. Free Sialic Acid Storage Disorders: Genes and Databases

Gene SymbolChromosomal LocusProtein NameLocus SpecificHGMD
SLC17A56q13SialinFinnish Disease Database (SLC17A5)SLC17A5

Data are compiled from the following standard references: gene symbol from HGNC; chromosomal locus, locus name, critical region, complementation group from OMIM; protein name from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B. OMIM Entries for Free Sialic Acid Storage Disorders (View All in OMIM)

269920INFANTILE SIALIC ACID STORAGE DISEASE; ISSD
604322SOLUTE CARRIER FAMILY 17 (SODIUM PHOSPHATE COTRANSPORTER), MEMBER 5; SLC17A5
604369SALLA DISEASE; SD

Molecular Genetic Pathogenesis

Mutations in SLC17A5 lead to defective sialin and elevated intralysosomal free sialic acid. How elevated intralysosomal free sialic acid causes pathology is not understood. Expression of sialin in the brain may explain part of the neurologic sequelae of Salla disease/ISSD [Aula et al 2004].

Gene structure. SLC17A5 consists of 11 exons, all of which are coding exons. Northern blot analysis shows major transcripts of 3.5 kb and 4.5 kb [Verheijen et al 1999]. For a detailed summary of gene and protein information, see Table A, Gene Symbol.

Benign allelic variants. One known benign variant in the coding region is p.Ala43Thr.

Pathogenic allelic variants. Different missense, nonsense, and splice site mutations, insertions, and deletions have been recognized as causing lysosomal free sialic acid storage disorders [Verheijen et al 1999, Aula et al 2000, Varho et al 2002, Kleta et al 2003, Martin et al 2003]. The p.Arg39Cys mutation is highly prevalent among affected individuals of Finnish heritage (see Prevalence).

Table 2. SLC17A5 Allelic Variants Discussed in This GeneReview

Class of Variant AlleleDNA Nucleotide Change Protein Amino Acid ChangeReference Sequences
Benignc.127G>Ap.Ala43ThrNM_012434​.4
NP_036566​.1
Pathogenicc.115C>Tp.Arg39Cys
c.406A>Gp.Lys136Glu

Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.

Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www​.hgvs.org). See Quick Reference for an explanation of nomenclature.

Normal gene product. The gene product of SLC17A5, sialin, is a 495-amino acid lysosomal membrane transport protein. Sialin has 42% sequence identity with transport proteins found in rat and mouse. Sialin is an integral lysosomal membrane transporter that exports free sialic acid from lysosomes [Renlund et al 1986, Mancini et al 1991]. Deficient or defective sialin results in excessive lysosomal storage of the free sialic acid produced by lysosomal degradation of glycoproteins and glycolipids.

Abnormal gene product. It is presumed that most SLC17A5 mutations result in defective or absent sialin. However, for two known mutations in SLC17A5, sialin is misrouted and fails to incorporate into the lysosomal membrane, which may be thought of as the functional equivalent of absent sialin [Aula et al 2002, Wreden et al 2005].

References

Literature Cited

  1. Aula N, Aula P. Prenatal diagnosis of free sialic acid storage disorders (SASD). Prenat Diagn. 2006;26:655–8. [PubMed: 16715535]
  2. Aula N, Jalanko A, Aula P, Peltonen L. Unraveling the molecular pathogenesis of free sialic acid storage disorders: altered targeting of mutant sialin. Mol Genet Metab. 2002;77:99–107. [PubMed: 12359136]
  3. Aula N, Kopra O, Jalanko A, Peltonen L. Sialin expression in the CNS implicates extralysosomal function in neurons. Neurobiol Dis. 2004;15:251–61. [PubMed: 15006695]
  4. Aula N, Salomaki P, Timonen R, Verheijen F, Mancini G, Mansson JE, Aula P, Peltonen L. The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation. Am J Hum Genet. 2000;67:832–40. [PMC free article: PMC1287888] [PubMed: 10947946]
  5. Aula P, Gahl WA. Disorders of free sialic acid storage. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic & Molecular Bases of Inherited Disease. 8 ed. New York, NY: McGraw-Hill; 2001:5109-20.
  6. Biancheri R, Rossi A, Mancini MG, Minetti C. Cerebellar white matter involvement in Salla disease. Neuroradiology. 2004;46:587–8. [PubMed: 15179531]
  7. Biancheri R, Rossi A, Verbeek HA, Schot R, Corsolini F, Assereto S, Mancini GMS, Verheijen FW, Minetti C, Filocamo M. Homozygosity for the p.K136E mutation in the SLC15A5 gene as cause of an Italian severe Salla disease. Neurogenetics. 2005;6:195–9. [PubMed: 16170568]
  8. Enns GM, Seppala R, Musci TJ, Weisiger K, Ferrell LD, Wenger DA, Gahl WA, Packman S. Clinical course and biochemistry of sialuria. J Inherit Metab Dis. 2001;24:328–36. [PubMed: 11486897]
  9. Erikson A, Aula N, Aula P, Mansson JE. Free sialic acid storage (Salla) disease in Sweden. Acta Paediatr. 2002;91:1324–7. [PubMed: 12578289]
  10. Ferreira H, Seppala R, Pinto R, Huizing M, Martins E, Braga AC, Gomes L, Krasnewich DM, Sa Miranda MC, Gahl WA. Sialuria in a Portuguese girl: clinical, biochemical, and molecular characteristics. Mol Genet Metab. 1999;67:131–7. [PubMed: 10356312]
  11. Froissart R, Cheillan D, Bouvier R, Tourret S, Bonnet V, Piraud M, Maire I. Clinical, morphological and molecular aspects of sialic acid storage disease manifesting in utero. J Med Genet. 2005;42:829–36. [PMC free article: PMC1735939] [PubMed: 15805149]
  12. Gahl WA, Krasnewich DM, Williams JC. Sialidoses. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Vol 66, chapter 18. Amsterdam, Netherlands: Elsevier; 1996:353-75.
  13. Gopaul KP, Crook MA. The inborn errors of sialic acid metabolism and their laboratory investigation. Clin Lab. 2006;52:155–69. [PubMed: 16584062]
  14. Grosso S, Berardi R, Farnetani MA, Margollicci M, Mancini MG, Morgese G, Balestri P. Multiple neuroendocrine disorder in Salla disease. J Child Neurol. 2001;16:775–7. [PubMed: 11669356]
  15. Helip-Wooley A, Kleta R, Gahl WA. Lysosomal free sialic acid storage disorders: salla disease and ISSD. In: Barranger JA, Cabrera-Salazar MA, eds. Lysosomal Storage Disorders. New York, NY: Springer; 2007:499-511.
  16. Alajoki L, Varho T, Posti K, Aula P, Korhonen T. Neurocognitive profiles in Salla disease. Dev Med Child Neurol. 2004;46:832–7. [PubMed: 15581157]
  17. Ishiwari K, Kotani M, Suzuki M, Pumbo E, Suzuki A, Kobayashi T, Ueno T, Fukushige T, Kanzaki T, Imada M, Itoh K, Akioka S, Tajima Y, Sakuraba H. Clinical, biochemical, and cytochemical studies on a Japanese Salla disease case associated with a renal disorder. J Hum Genet. 2004;49:656–63. [PubMed: 15635485]
  18. Kleta R, Aughton DJ, Rivkin MJ, Huizing M, Strovel E, Anikster Y, Orvisky E, Natowicz M, Krasnewich D, Gahl WA. Biochemical and molecular analyses of infantile free sialic acid storage disease in North American children. Am J Med Genet. 2003;120A:28–33. [PubMed: 12794688]
  19. Kleta R, Morse RP, Orvisky E, Krasnewich D, Alroy J, Ucci AA, Bernardini I, Wenger DA, Gahl WA. Clinical, biochemical, and molecular diagnosis of a free sialic acid storage disease patient of moderate severity. Mol Genet Metab. 2004;82:137–43. [PubMed: 15172001]
  20. Landau D, Cohen D, Shalev H, Pinsk V, Yerushalmi B, Zeigler M, Birk OS. A novel mutation in the SLC17A5 gene causing both severe and mild phenotypes of free sialic acid storage disease in one inbred Bedouin kindred. Mol Genet Metab. 2004;82:167–72. [PubMed: 15172005]
  21. Lemyre E, Russo P, Melancon SB, Gagne R, Potier M, Lambert M. Clinical spectrum of infantile free sialic acid storage disease. Am J Med Genet. 1999;82:385–91. [PubMed: 10069709]
  22. Leroy JG, Seppala R, Huizing M, Dacremont G, De Simpel H, Van Coster RN, Orvisky E, Krasnewich DM, Gahl WA. Dominant inheritance of sialuria, an inborn error of feedback inhibition. Am J Hum Genet. 2001;68:1419–27. [PMC free article: PMC1226128] [PubMed: 11326336]
  23. Linnankivi T, Lonnqvist T, Autti T. A case of Salla disease with involvement of the cerebellar white matter. Neuroradiology. 2003;45:107–9. [PubMed: 12592494]
  24. Mancini GM, Beerens CE, Aula PP, Verheijen FW. Sialic acid storage diseases. A multiple lysosomal transport defect for acidic monosaccharides. J Clin Invest. 1991;87:1329–35. [PMC free article: PMC295166] [PubMed: 2010546]
  25. Martin RA, Slaugh R, Natowicz M, Pearlman K, Orvisky E, Krasnewich D, Kleta R, Huizing M, Gahl WA. Sialic acid storage disease of the Salla phenotype in American monozygous twin female sibs. Am J Med Genet A. 2003;120A:23–7. [PubMed: 12794687]
  26. Mochel F, Yang B, Barritault J, Thompson JN, Engelke UF, McNeill NH, Benko WS, Kaneski CR, Adams DR, Tsokos M, Abu-Asab M, Huizing M, Seguin F, Wevers RA, Ding J, Verheijen FW, Schiffmann R. Free sialic acid storage disease without sialuria. Ann Neurol. 2009;65:753–7. [PMC free article: PMC3508714] [PubMed: 19557856]
  27. Renlund M, Aula P, Raivio KO, Autio S, Sainio K, Rapola J, Koskela SL. Salla disease: a new lysosomal storage disorder with disturbed sialic acid metabolism. Neurology. 1983;33:57–66. [PubMed: 6681560]
  28. Renlund M, Tietze F, Gahl WA. Defective sialic acid egress from isolated fibroblast lysosomes of patients with Salla disease. Science. 1986;232:759–62. [PubMed: 3961501]
  29. Salomaki P, Aula N, Juvonen V, Renlund M, Aula P. Prenatal detection of free sialic acid storage disease: genetic and biochemical studies in nine families. Prenat Diagn. 2001;21:354–8. [PubMed: 11360275]
  30. Seppala R, Lehto VP, Gahl WA. Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene define the disease sialuria and the allosteric site of the enzyme. Am J Hum Genet. 1999;64:1563–9. [PMC free article: PMC1377899] [PubMed: 10330343]
  31. Sonderby Christensen P, Kaad PH, Ostergaard JR. Two cases of Salla disease in Danish children. Acta Paediatr. 2003;92:1357–8. [PubMed: 14696864]
  32. Sonninen P, Autti T, Varho T, Hamalainen M, Raininko R. Brain involvement in Salla disease. AJNR Am J Neuroradiol. 1999;20:433–43. [PubMed: 10219409]
  33. Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr. 1999;46:409–40. [PubMed: 10645471]
  34. Valianpour F, Abeling NG, Duran M, Huijmans JG, Kulik W. Quantification of free sialic acid in urine by HPLC-electrospray tandem mass spectrometry: a tool for the diagnosis of sialic acid storage disease. Clin Chem. 2004;50:403–9. [PubMed: 14684624]
  35. Varho T, Jaaskelainen S, Tolonen U, Sonninen P, Vainionpaa L, Aula P, Sillanpaa M. Central and peripheral nervous system dysfunction in the clinical variation of Salla disease. Neurology. 2000;55:99–104. [PubMed: 10891913]
  36. Varho TT, Alajoki LE, Posti KM, Korhonen TT, Renlund MG, Nyman SR, Sillanpaa ML, Aula PP. Phenotypic spectrum of Salla disease, a free sialic acid storage disorder. Pediatr Neurol. 2002;26:267–73. [PubMed: 11992753]
  37. Verheijen FW, Verbeek E, Aula N, Beerens CE, Havelaar AC, Joosse M, Peltonen L, Aula P, Galjaard H, van der Spek PJ, Mancini GM. A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases. Nat Genet. 1999;23:462–5. [PubMed: 10581036]
  38. Wreden CC, Wlizla M, Reimer RJ. Varied mechanisms underlie the free sialic acid storage disorders. J Biol Chem. 2005;280:1408–16. [PubMed: 15516337]

Suggested Reading

  1. Aula P, Gahl WA. Disorders of free sialic acid storage. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B, eds. The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID). New York, NY: McGraw-Hill. Chap 200. Available online. 2014. Accessed 6-10-14.

Chapter Notes

Author Notes

David Adams, MD, PhD is a pediatrician, medical geneticist, and biochemical geneticist who performs clinical and basic research into rare diseases at the National Institutes of Health.

William A Gahl, MD, PhD is a pediatrician, medical geneticist, and biochemical geneticist who performs clinical and basic research into rare diseases at the National Institutes of Health.

Revision History

  • 6 June 2013 (me) Comprehensive update posted live
  • 3 July 2008 (me) Comprehensive update posted live
  • 4 October 2005 (me) Comprehensive update posted to live Web site
  • 13 June 2003 (ca) Review posted to live Web site
  • 28 February 2003 (wg) Original submission

Pursuant to 17 USC Section 105 of the United States Copyright Act, the GeneReview "Free Sialic Acid Storage Disorders" is in the public domain in the United States of America.

Copyright © 1993-2014, University of Washington, Seattle. All rights reserved.

For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.

For questions regarding permissions: ude.wu@tssamda.

Bookshelf ID: NBK1470PMID: 20301643
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Tests in GTR by Gene

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed
  • Gene
    Gene records cited in chapters on the NCBI bookshelf. Links are provided by the authors or the NCBI Bookshelf staff.

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...